Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer

Liang Huang1 Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Qi Liu2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;3 Department of Radiation Oncology, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, China

Sheng Chen1 Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Zhiming Shao1 Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaCorrespondence[email protected]

Pages 5739-5744 | Published online: 01 Dec 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

AbramsonVGLehmannBDBallingerTJPietenpolJASubtyping of triple-negative breast cancer: implications for therapyCancer2015121181625043972
PubMedGoogle Scholar
LehmannBDBauerJAChenXSandersMEChakravarthyABShyrYPietenpolJAIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
PubMed Web of Science ®Google Scholar
CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
PubMed Web of Science ®Google Scholar
LiedtkeCMazouniCHessKRResponse to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerJ Clin Oncol20082681275128118250347
PubMed Web of Science ®Google Scholar
CareyLADeesECSawyerLThe triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesClin Cancer Res20071382329233417438091
PubMed Web of Science ®Google Scholar
ChenXSNieXQChenCMWeekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancerAnn Oncol201021596196720211870
PubMed Web of Science ®Google Scholar
CortazarPZhangLUntchMAbstract P1-14-20: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)Cancer Research20127224 SupplS1S11
Google Scholar
PetrelliFBarniSBregniGde BraudFDi CosimoSPlatinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trialsBreast Cancer Res Treat2016160342543727770282
PubMedGoogle Scholar
OgstonKNMillerIDPayneSA new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survivalBreast200312532032714659147
PubMed Web of Science ®Google Scholar
HuXCZhangJXuBHCisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trialLancet Oncol201516443644625795409
PubMed Web of Science ®Google Scholar
ByrskiTGronwaldJHuzarskiTPathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapyJ Clin Oncol201028337537920008645
PubMed Web of Science ®Google Scholar
SharmaPLopez-TarruellaSGarcia-SaenzJAEfficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohortsClin Cancer Res201723364965727301700
PubMed Web of Science ®Google Scholar
DecatrisMPSundarSO’ByrneKJPlatinum-based chemotherapy in metastatic breast cancer: current statusCancer Treat Rev2004301538114766126
PubMed Web of Science ®Google Scholar
SikovWMBerryDAPerouCMImpact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)J Clin Oncol2015331132125092775
PubMed Web of Science ®Google Scholar
von MinckwitzGSchneeweissALoiblSNeoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialLancet Oncol201415774775624794243
PubMed Web of Science ®Google Scholar
PetrelliFCoinuABorgonovoKCabidduMGhilardiMLonatiVBarniSThe value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysisBreast Cancer Res Treat2014144222323224557340
PubMed Web of Science ®Google Scholar
HurleyJReisIMRodgersSEThe use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patientsBreast Cancer Res Treat2013138378379423542956
PubMed Web of Science ®Google Scholar
Llombart-CussacABermejoBVillanuevaCSOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancerBreast Cancer Res Treat2015154235135726536871
PubMed Web of Science ®Google Scholar
von MinckwitzGMullerBMLoiblSCytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapyJ Clin Oncol201129162150215721519019
PubMedGoogle Scholar
MaXWangXHuangJBevacizumab addition in neoadjuvant treatment increases the pathological complete response rates in patients with HER-2 negative breast cancer especially triple negative breast cancer: a meta-analysisPLoS One2016118e016014827579484
PubMedGoogle Scholar
SikovWMAssessing the role of platinum agents in aggressive breast cancersCurr Oncol Rep2015172325665554
PubMedGoogle Scholar
SikovWMDizonDSStrengerRFrequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group StudyJ Clin Oncol200927284693470019720916
PubMed Web of Science ®Google Scholar
SilverDPRichardsonALEklundACEfficacy of neoadjuvant Cisplatin in triple-negative breast cancerJ Clin Oncol20102871145115320100965
PubMed Web of Science ®Google Scholar
EzzatAAIbrahimEMAjarimDSPhase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patientsBr J Cancer200490596897414997191
PubMedGoogle Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date